MiNK Therapeutics, Inc.
INKT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $44 | $49 | $51 | $54 |
| Gross Profit | -$44 | -$49 | -$51 | -$54 |
| % Margin | – | – | – | – |
| R&D Expenses | $1,143 | $1,839 | $1,262 | $1,406 |
| G&A Expenses | $0 | $1,849 | $0 | $0 |
| SG&A Expenses | $1,803 | $1,849 | $1,220 | $755 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$49 | $0 | $0 |
| Operating Expenses | $2,946 | $3,640 | $2,482 | $2,161 |
| Operating Income | -$2,990 | -$3,688 | -$2,533 | -$2,215 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $102 | -$549 | -$234 | -$249 |
| Pre-Tax Income | -$2,888 | -$4,238 | -$2,767 | -$2,464 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2,888 | -$4,238 | -$2,767 | -$2,464 |
| % Margin | – | – | – | – |
| EPS | -0.65 | -1.06 | -0.7 | -0.65 |
| % Growth | 38.7% | -51.4% | -7.7% | – |
| EPS Diluted | -0.65 | -1.06 | -0.7 | -0.65 |
| Weighted Avg Shares Out | 4,443 | 3,982 | 3,965 | 3,773 |
| Weighted Avg Shares Out Dil | 4,443 | 3,982 | 3,965 | 3,773 |
| Supplemental Information | – | – | – | – |
| Interest Income | $55 | $0 | $14 | $40 |
| Interest Expense | – | $0 | $0 | $0 |
| Depreciation & Amortization | $44 | $49 | $51 | $54 |
| EBITDA | -$2,844 | -$4,189 | -$2,716 | -$2,410 |
| % Margin | – | – | – | – |